Bionano Genomics, Inc. (BNGO)

Bionano Genomics' stock has experienced a substantial decrease over the last six months. Bionano reported Q3 2025 revenue of $7.4 million, a 21% increase year-over-year. Bionano completed a public offering, raising $10 million through the sale of 5,000,000 shares of common stock at $2.00 per share. The company held its Q2 2025 financial results call. Analysts have provided a wide range for BNGO's future price, with a maximum estimate of $8.00 and a minimum of $7.00. Shareholders have experienced substantial dilution in the past year.

Information directly detailing the demand seasonality for Bionano Genomics' products and services is not explicitly available. The company's business model is driven by recurring revenue from instruments and consumables, suggesting a relatively consistent demand once systems are installed. The company's strategic focus on increasing the utilization of its existing optical genome mapping (OGM) systems among its core routine-use customers indicates a push for steady, ongoing demand for its consumables. The impact of the new Category 1 CPT code for hematologic malignancies is anticipated to be a catalyst for increased utilization and customer acquisition, which could introduce some cyclicality related to clinical adoption and reimbursement cycles.

Bionano Genomics, Inc. is a life sciences instrumentation company specializing in genome analysis solutions, operating within the Healthcare sector. It develops and commercializes high-resolution genome analysis tools designed to map structural variants and large-scale genomic rearrangements. Its products include Saphyr and Stratys Systems, Saphyr Chips, Bionano Prep Kits and DNA Labeling Kits, Ionic Purification System, and software solutions like Bionano Access™ and Bionano Solve™. Through its subsidiary Lineagen, Inc., Bionano provides diagnostic testing and contract genome mapping services.

Bionano Genomics, Inc. provides genome analysis solutions globally, with operations in the Americas, Europe, the Middle East, Africa (EMEA), and the Asia Pacific region. The EMEA region generates the majority of its revenue. The company is headquartered in San Diego, California, United States.

Bionano Genomics has focused on highlighting the value and expanding role of its optical genome mapping (OGM) technology. Numerous publications have demonstrated the value of OGM, with 97 new publications in Q3 2025 alone. Bionano highlighted global momentum behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting in October 2025. The company has emphasized a strategic shift towards optimizing the utilization of existing OGM systems among core customers. Despite scientific advancements, the company's stock performance has been poor, which could impact investor confidence.

Bionano Genomics has a mixed ownership structure comprising institutional shareholders, insiders, and retail investors. Institutional investors hold approximately 0.43% to 2.40% of the company's stock. Insiders own approximately 1.97% to 252.41% of the company. Retail investors hold a significant portion, approximately 96.98% of the stock.